#3513
Comprehensive molecular analysis of prognostic groups in Neuroendocrine Neoplasms (NENs) identifies key genes and potential regulatory mechanisms
Introduction:
MiRNAs are key regulators of multiple molecular processes, including tumorigenesis and cancer progression. However, very few studies have assessed their role in NENs. In a previous study, we identified a miRNA signature that defined 3 prognostic groups in 86 patients with lung and gastroenteropancreatic (GEP) NENs. Here, we explore up- and downstream mechanisms underlying this miRNA signature.
Conference:
Presenting Author:
Lens-Pardo A
Authors:
Lens-Pardo A,
Espinosa-Olarte P,
Carretero C,
Molina-Pinelo S,
Robles C,
Keywords:
miRNAs,
Signature,
omics,
Molecular,
Neuroendocrine Neoplasia,
Lung,
Gastroenteropancreatic,
#3275
MicroRNA prognostic signature in neuroendocrine neoplasias (NENs) of lung and GEP origin: In silico analysis of target genes and pathways
Introduction:
Molecular knowledge of NENs has increased in the last years. Nevertheless, the lack of in vivo models makes it difficult to guide functional experiments to better understand the biological implications of described molecular alterations. In this context, and as miRNAs contribute to regulate gene expression, we performed an in silico analysis to explore target genes and involved pathways regulated by an 8-miRNA prognostic signature that we recently developed in NENs, that stratified patients in 3 prognostic groups (Espinosa-Olarte P et al, ESMO 2020).
Conference:
18th Annual ENETS Concerence (2021)
Presenting Author:
Authors:
Espinosa Olarte P,
Soldevilla B,
Carretero-Puche C,
Molina-Pinelo S,
Robles C,
Keywords:
neuroendocrine neoplasia,
miRNAs,
genes,
pathways,
prognosis,
#3030
Targeting CXCR4 and Thioredoxin Reductase in Theranostics of Atypical Carcinoid and Neuroendocrine Carcinoma
Introduction:
Atypical carcinoid and small cell lung cancer (SCLC) are currently incurable. There is thus a critical need for new diagnostic and therapeutic strategies for lung neuroendocrine neoplasms (LNEN). Chemokine receptor 4 (CXCR4), a G protein coupled receptor and theranostic target, plays a crucial role in metastases of LNEN. We hypothesize combination of thioredoxin reductase (TR) inhibitor represents a metabolic strategy to enhance cytotoxicity in peptide-receptor radionuclide therapy (PRRT) of LNEN.
Conference:
17th Annual ENETSConcerence (2020)
Presenting Author:
Liu D
Authors:
Liu D,
Fath M,
Robles Planells C,
Balk E,
Bellizzi A,
Keywords:
CXCR4,
thioredoxin reductase inhibitor,
theranostics,
atypical carcinoid,
small cell lung cancer,
